DC-CTL therapeutics - Zhengzhou Revo-Gene Technology
Alternative Names: DC CTL; Dendritic cell-cytotoxic T lymphocytesLatest Information Update: 28 Aug 2024
At a glance
- Originator Zhengzhou Revo-Gene Technology
- Class Antineoplastics; Cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 06 Aug 2024 Clinical trials in Solid tumours (Parenteral)
- 01 Aug 2024 Zhengzhou Revo-Gene Technology plans a clinical trial for Solid tumour (Combination therapy) in August 2024 (Parenteral, Injection) (NCT06524024).